1
|
Gross D. Thromboembolic Phenomena and the use of the Pig as an Appropriate Animal Model for Research on Cardiovascular Devices. Int J Artif Organs 2018. [DOI: 10.1177/039139889702000402] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- D.R. Gross
- Department of Veterinary Biosciences, College of Veterinary Medicine, University of Illinois, Urbana-Champaign - USA
| |
Collapse
|
2
|
Neville NT, Parton J, Harwood JL, Jackson SK. The activities of monocyte lysophosphatidylcholine acyltransferase and coenzyme A-independent transacylase are changed by the inflammatory cytokines tumor necrosis factor alpha and interferon gamma. Biochim Biophys Acta Mol Cell Biol Lipids 2005; 1733:232-8. [PMID: 15863370 DOI: 10.1016/j.bbalip.2004.12.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2004] [Revised: 12/17/2004] [Accepted: 12/20/2004] [Indexed: 11/26/2022]
Abstract
Alteration of membrane phospholipid fatty acid compositions has been shown to be important for leukocyte inflammatory responses. Such modification of the molecular species of these lipid classes requires deacylation and reacylation reactions and for phosphatidylcholines, lysophosphatidylcholine acyltransferase (LPCAT) and a coenzyme A-independent transacylase (CoAIT) can each be involved. Since previous studies have shown a significant IFNgamma- and TNFalpha-induced modification of phosphatidylcholine species, we have examined whether these inflammatory cytokines alter the activity of reacylation enzymes in the human monocyte cell line MonoMac 6 (MM6). IFN-gamma caused a significant increase in the activity of the LPCAT and CoAIT enzymes in the microsomal fraction at concentrations and over a time-course consistent with an important role for these enzymes in the sensitization (priming) of monocytes. In contrast, TNFalpha was found to significantly increase the activity of the CoAIT by 50% over controls in MM6 cells after 30 min incubation with the cytokine, but decreased LPCAT activity by 65% after 24 h incubation. Such data imply that CoAIT is important for the remodelling of phospholipid composition, which is seen during the acute response of cells to TNFalpha. The results provide further information to emphasise the role of acyltransferases as part of the molecular mechanism underlying inflammation.
Collapse
|
3
|
Roy Baker R, Chang HY. MgATP may depress de novo neuronal nuclear PAF generation by promoting the formation of alkylacylglycerophosphate, an inhibitor of alkylglycerophosphate acetyltransferase. BIOCHIMICA ET BIOPHYSICA ACTA 2002; 1585:44-9. [PMID: 12457714 DOI: 10.1016/s1388-1981(02)00318-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
MgATP substantially inhibited 1-alkyl-sn-glycero-3-phosphate (AGP) acetyltransferase found in neuronal nuclei. Other nucleotides and the ATP analogue AMP-PNP did not show a comparable inhibition. MgATP inhibition decreased in the presence of bovine serum albumin or the fatty acyl CoA synthetase inhibitor, Triacsin C. MgATP inhibition increased when nuclei were preincubated in 50 mM Tris-HCl (pH 7.4)/1 mM MgCl(2) at 37 degrees C, and preincubations elevated levels of nuclear free fatty acid. Exogenous free fatty acid, added to the acetylation incubations, increased the inhibition seen in the presence of MgATP. Oleoyl CoA, in the absence of MgATP, also inhibited AGP acetylation. These results suggested that MgATP supported the conversion of nuclear free fatty acids to fatty acyl CoA. Fatty acyl CoA may directly inhibit nuclear AGP acetyltransferase, but inhibition brought about by MgATP was competitive for the AGP substrate, suggesting an inhibitor close in structure to AGP. 1-Hexadecyl-2-arachidonoyl-sn-glycero-3-phosphate was identified as a competitive inhibitor for AGP in the acetylation reaction. Neuronal nuclei can convert AGP to 1-alkyl-2-acyl-sn-glycero-3-phosphate (AAcylGP), a reaction dependent upon MgATP and the presence of acetyl CoA or free CoA. This nuclear acylation was increased by free fatty acid addition and was seen using oleoyl CoA in the absence of MgATP. Nuclear AAcylGP formation was inhibited by bovine serum albumin and by Triacsin C. Thus, nuclear AGP acetyltransferase may be regulated by AGP acyltransferase activity and the availability of MgATP, a nucleotide that is rapidly lost during brain ischemia.
Collapse
Affiliation(s)
- R Roy Baker
- Department of Biochemistry, University of Toronto, Room 5202, Medical Sciences Building, 1 King's College Circle, M5S 1A8, Toronto, Ontario, Canada.
| | | |
Collapse
|
4
|
Shinomiya S, Naraba H, Ueno A, Utsunomiya I, Maruyama T, Ohuchida S, Ushikubi F, Yuki K, Narumiya S, Sugimoto Y, Ichikawa A, Oh-ishi S. Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem Pharmacol 2001; 61:1153-60. [PMID: 11301049 DOI: 10.1016/s0006-2952(01)00586-x] [Citation(s) in RCA: 132] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
To know which receptors of prostaglandins are involved in the regulation of TNFalpha and interleukin 10 (IL-10) production, we examined the production of these cytokines in murine peritoneal macrophages stimulated with zymosan. The presence of PGE(2) or the PGI(2) analog carbacyclin in the medium reduced the TNFalpha production to one-half, whereas IL-10 production increased several fold; and indomethacin caused the reverse effects, suggesting that endogenous prostaglandins may have a regulatory effect on the cytokine production. Among prostaglandin E (EP) receptor-selective synthetic agonists, EP2 and EP4 agonists caused down-regulation of the zymosan-induced TNFalpha production, but up-regulation on the IL-10 production; while EP1 and EP3 agonists showed no effect. Macrophages harvested from prostaglandin I (IP) receptor-deficient mice showed the up- and down-regulatory effects on the cytokine production by the EP2 and EP4 agonists or PGE(2), but no effect was obtained by carbacyclin. On the contrary, macrophages from EP2-deficient mice showed the effect by PGE(2), carbacyclin, and the EP4 agonist, but not by the EP2 agonist; and the cells from EP4-deficient mice showed the effect by PGE(2), carbacyclin, and EP2 agonist, but not by the EP4 agonist. These functional effects of prostaglandins well accorded with the mRNA expression of TNFalpha and IL-10 when such expression was examined by the RT-PCR method. The peritoneal macrophages from normal mice expressed IP, EP2, and EP4 receptors, but not EP1 and EP3, when examined by RT-PCR. Thus the results suggest that PGI(2) and PGE(2) generated simultaneously with cytokines by macrophages treated with zymosan may influence the cytokine production through IP, EP2, and EP4 receptors.
Collapse
MESH Headings
- Animals
- Cyclic AMP/pharmacology
- Dinoprostone/metabolism
- Epoprostenol/metabolism
- Female
- Interleukin-10/metabolism
- Macrophages, Peritoneal/drug effects
- Macrophages, Peritoneal/metabolism
- Male
- Mice
- Mice, Inbred C57BL
- RNA, Messenger/biosynthesis
- RNA, Messenger/drug effects
- Receptors, Prostaglandin/agonists
- Receptors, Prostaglandin/deficiency
- Receptors, Prostaglandin/genetics
- Receptors, Prostaglandin/metabolism
- Receptors, Prostaglandin E/agonists
- Receptors, Prostaglandin E/metabolism
- Tumor Necrosis Factor-alpha/metabolism
- Zymosan/pharmacology
Collapse
Affiliation(s)
- S Shinomiya
- Department of Pharmacology, School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Baker RR, Chang HY. Evidence for two distinct lysophospholipase activities that degrade lysophosphatidylcholine and lysophosphatidic acid in neuronal nuclei of cerebral cortex. BIOCHIMICA ET BIOPHYSICA ACTA 1999; 1438:253-63. [PMID: 10320808 DOI: 10.1016/s1388-1981(99)00057-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Neuronal nuclei were isolated from immature rabbit cerebral cortex and nuclear lysophospholipase activities studied using two different 1-acyl lysophospholipids: lysophosphatidylcholine (lysoPC) and lysophosphatidic acid (lysoPA). Our interest in these two lysolipids arose from the observation that lysoPA could promote the acetylation of lysoPC by substantially inhibiting a very active nuclear lysoPC lysophospholipase activity, in a competitive manner (R.R. Baker, H. -y. Chang, Mol. Cell. Biochem. (1999) in press). As there was also evidence for nuclear lysoPA deacylation, it was of interest to see whether one activity could possibly utilize both lysolipid substrates. We now have evidence for two separate lysophospholipase activities in neuronal nuclei. The lysoPC lysophospholipase activity was the more active, more highly enriched in the neuronal nuclei, and showed optimal activity at pH 8.4-9, while the lysoPA lysophospholipase activity was maintained over a much broader pH range. The lysoPC activity was substantially inhibited by free fatty acid, and showed considerable stimulation by serum albumin, while the activity utilizing lysoPA was much less affected by these agents. When lysoPC was added to incubations containing radioactive lysoPA, there was no significant inhibition found in rates of release of radioactive fatty acid, indicating that the lysoPA lysophospholipase activity did not utilize the lysoPC substrate. In incubations with lysoPC, MgATP and CoA brought about a sizable formation of phosphatidylcholine whose radioactivity was equally distributed between the sn-1 and sn-2 positions suggesting labelling both directly from the lysoPC substrate and from fatty acid produced by the lysophospholipase activity. By comparison, with the radioactive lysoPA substrate, MgATP and CoA promoted relatively lower levels of phosphatidic acid formation whose principal labelling came directly from the radioactive lysoPA. Largely because of the high activity of the nuclear lysoPC lysophospholipase, there is considerable potential in the neuronal nucleus to limit the use of lysoPC in other reactions, such as the formation of acylPAF (1-acyl analogue of platelet activating factor). It is of interest that conditions associated with brain ischaemia such as increased free fatty acid levels, falling pH and declines in MgATP may allow a preservation of neuronal nuclear lysoPC levels for acetylation. The existence of a separate lysophospholipase activity for lysoPA allows an independent control of lysoPA which can serve as an important regulator of the nuclear lysoPC lysophospholipase.
Collapse
Affiliation(s)
- R R Baker
- Department of Biochemistry, Room 5202, Medical Sciences Bldg., University of Toronto, Toronto, Ont. M5S 1A8, Canada
| | | |
Collapse
|
6
|
Baker RR, Chang H. MgATP has different inhibitory effects on the use of 1-acyl-lysophosphatidylcholine and lyso platelet-activating factor acceptors by neuronal nuclear acetyltransferase activities. BIOCHIMICA ET BIOPHYSICA ACTA 1998; 1392:351-60. [PMID: 9630721 DOI: 10.1016/s0005-2760(98)00050-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The inhibitory effects of MgATP on neuronal nuclear acetyltransferase activities were studied using lyso platelet-activating factor (lyso-PAF, 1-alkyl-sn-glycero-3-phosphocholine) and lysophosphatidylcholine (lyso-PC, 1-acyl-sn-glycero-3-phosphocholine). The nuclear (N1) acetylation of lyso-PC was more profoundly inhibited by MgATP. MgATP did not alter the apparent Km for acetyl-CoA in either acetylation reaction. The inhibitory effects of MgATP were not seen for other nucleotides or MgAMP-PCP. Kinase inhibitors such as staurosporine (1 microM), chelerythrine, and R59022 (diglyceride kinase inhibitor I) did not block the MgATP inhibition of either acetylation. However, the addition of phospholipids to the assays indicated a selective inhibitory effect for PIP (25-50 microM) in the nuclear acetylation of lyso-PAF. When N1 was incubated with [gamma-33P]ATP, phosphatidic acid and PIP were the principal radioactive lipid products. While the extent of MgATP inhibition of lyso-PAF acetylation was similar at different concentrations of lyso-PAF, increasing lyso-PC concentrations greatly decreased the MgATP inhibition seen in lyso-PC acetylations. Nuclear envelopes prepared in the presence of PMSF, and fraction N1 exposed to PMSF, did not show the inhibitory effect of MgATP on lyso-PC acetylation. PMSF (an inhibitor of certain phospholipase and lysophospholipase activities) did not reduce the MgATP inhibition of lyso-PAF acetylation. Arachidonoyl trifluoromethylketone, an inhibitor of cytosolic phospholipases A2 and of lysophospholipase activity associated with cPLA2, also blocked the inhibitory effect of MgATP on lyso-PC acetylation. Using radioactive lyso-PC substrate, fraction N1 produced labeled free fatty acid and phosphatidylcholine. In the presence of acetyl-CoA, the production of radioactive phosphatidylcholine increased almost 6-fold when MgATP was also included in these incubations. In the presence of MgATP and acetyl-CoA, PMSF reduced the levels of radioactive free fatty acid and phosphatidylcholine derived from lyso-PC, while Triacsin C, an inhibitor of acyl CoA synthetase, decreased phosphatidylcholine labeling. These findings suggest that MgATP inhibition of lyso-PC acetylation results from a loss of lyso-PC substrate that is largely mediated by nuclear lysophospholipase, acyl-CoA synthetase and lyso-PC acylation. Thus the neuronal nuclear production of Acyl PAF may be regulated by paths that compete for the lyso-PC substrate. In contrast, the acetylation of lyso-PAF is inhibited by PIP, a product of nuclear PI kinase reactions.
Collapse
Affiliation(s)
- R R Baker
- Division of Neurology, Department of Medicine, Clinical Science Division, Room 6368, Medical Sciences Bldg., University of Toronto, Toronto, Ont., M5S 1A8, Canada
| | | |
Collapse
|
7
|
Feuerstein G, Rabinovici R, Leor J, Winkler JD, Vonhof S. Platelet-activating factor and cardiac diseases: therapeutic potential for PAF inhibitors. JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING 1997; 15:255-84. [PMID: 9041476 DOI: 10.1016/s0929-7855(96)00562-7] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Platelet-activating factor (PAF) is a potent phospholipid mediator released from inflammatory cells in response to diverse immunologic and non-immunologic stimuli. Animal studies have implicated PAF as a major mediator involved in coronary artery constriction, modulation of myocardial contractility and the generation of arrhythmias which may bear on cardiac disorders such as ischemia, infarction and sudden cardiac death. PAF effects are induced by direct actions of PAF on cardiac tissue to modify chronotropic and inotropic activity, or indirectly via the release of eicosanoids such as thromboxane A2 (TXA2), leukotrienes (LT) or cytokines (TNF alpha). The development of selective, high affinity PAF receptor antagonists has permitted investigations on the role of PAF in experimental animal models of cardiac injury. In vivo and in vitro studies strongly suggest that PAF receptor antagonists might convey therapeutic benefits in ischemic conditions and certain arrhythmias. In addition, PAF antagonists might have a cardiac allograft-preservation effect. Although clinical studies with PAF receptor antagonists in patients with cardiac diseases have not yet been reported, the experimental results to date suggest that PAF receptor antagonists might be useful in some specific cardiac disorders in humans.
Collapse
Affiliation(s)
- G Feuerstein
- Department of Cardiovascular, UW2511, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939, USA
| | | | | | | | | |
Collapse
|
8
|
Zhelev DV. Exchange of monooleoylphosphatidylcholine with single egg phosphatidylcholine vesicle membranes. Biophys J 1996; 71:257-73. [PMID: 8804609 PMCID: PMC1233477 DOI: 10.1016/s0006-3495(96)79222-6] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
In a previous paper we described the experiments and the framework of a model for the exchange of monooleoylphosphatidylcholine with a single egg phosphatidylcholine membrane. In the present paper a model is presented that relates the experimentally measured apparent characteristics of the overall kinetics of lysolipid exchange to the true rates of lysolipid exchange and interbilayer transfer. It is shown that the adsorption of the lysolipid follows two pathways: one through the adsorption of lipid monomers and other through the fusion of micelles. The desorption of lysolipid follows a single pathway, namely, the desorption of monomers. The overall rate of fast desorption under convective flow conditions gives the true rate of monomer desorption from the outer membrane monolayer. The overall rate of both slow lysolipid uptake and slow desorption gives the rate of interbilayer transfer. Because of the uneven distribution of lysolipid between the two monolayers during its uptake, one of the membrane monolayers is apparently extended relative to the other. This relative extension of one of the monolayers induces a monolayer tension. The induced monolayer tension can increase up to 7 mN.m-1, when most of the intercalated lysolipid only partitions into the monolayer facing the lysolipid solution. This value is similar to the measured value for the critical monolayer tension of membrane failure, which is on the order of 5 mN.m-1. The similarity of the magnitudes of the induced monolayer tension during monooleoylphosphatidylcholine exchange and the monolayer tension of membrane failure suggests that the interbilayer lipid transfer may be affected by the formation of short living membrane defects. Furthermore, the pH-induced interbilayer exchange of phosphatidylglycerol is considered. In this case, it is shown that the rate of interbilayer transfer is a function of the phosphatidylglycerol concentration in the membrane.
Collapse
Affiliation(s)
- D V Zhelev
- Department of Mechanical Engineering and Materials Science, Duke University, Durham, North Carolina 27708-0300, USA.
| |
Collapse
|
9
|
Naraba H, Ueno A, Matsumoto H, Oh-ishi S. Inhibitory effect of arachidonic acid on platelet-activating factor production in rat neutrophils. Eur J Pharmacol 1996; 302:117-21. [PMID: 8790999 DOI: 10.1016/0014-2999(96)00029-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Platelet-activating factor production in rat neutrophils in response to opsonized zymosan was suppressed dose dependently in the presence of 10-100 microM arachidonic acid. The amount of lyso-PAF was also reduced by these doses of arachidonic acid. Phospholipase A2 activity was not changed by addition of arachidonic acid up to 100 microM, but acetyltransferase activity was slightly reduced at a 100 microM concentration of arachidonic acid. Pretreatment with indomethacin did not alter the inhibitory effect of arachidonic acid on PAF production, indicating no involvement of cyclooxgenase products. Triacsin C, an acyl-CoA synthetase inhibitor, reversed the arachidonic acid-induced suppression of lyso-PAF and PAF production, suggesting that arachidonic acid might exert its inhibition via the acylation pathway of lyso-PAF to reduce the availability of lyso-PAF.
Collapse
Affiliation(s)
- H Naraba
- Department of Pharmacology, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan
| | | | | | | |
Collapse
|